Drug, program or condition

The PBS subsidises pasireotide and pegvisomant for patients with acromegaly.

The PBS subsidises biological medicines for patients with ankylosing spondylitis.

The PBS subsidises biological medicines for patients with severe active juvenile idiopathic arthritis.

The PBS subsidises biological agents for adult patients with severe psoriatic arthritis.

The PBS subsidises biological agents for patients with severe active rheumatoid arthritis.

The PBS subsidises tocilizumab for patients with systemic juvenile idiopathic arthritis.

The PBS subsidises biological agents for patients with severe asthma.

The PBS subsidises eculizumab for patients with atypical haemolytic uraemic syndrome (aHUS).

The PBS subsidises sonidegib and vismodegib for patients with metastatic or locally advanced basal cell carcinoma (BCC).

The PBS subsidises lapatinib, pertuzumab, trastuzumab, trastuzumab deruxtecan and trastuzumab emtansine for patients with breast cancer.

The PBS subsidises mepolizumab for patients with chronic rhinosinusitis with nasal polyps (CRSwNP).

The PBS subsidises biological medicines for adult patients with severe Crohn’s disease.

The PBS subsidises biological agents for patients with complex refractory fistulising Crohn's disease.

The PBS subsidises biological agents for paediatric patients with severe refractory Crohn's disease.

The PBS subsidises ivacaftor, lumacaftor+ivacaftor, tezacaftor+ivacaftor and elexacaftor+tezacaftor+ivacaftor for patients with cystic fibrosis.

The PBS subsidises aflibercept, dexamethasone intravitreal implant, faricimab and ranibizumab for patients with diabetic macular oedema.

The PBS subsidises aflibercept, dexamethasone intravitreal implant and ranibizumab for patients with branched or central retinal vein occlusion (BRVO or CRVO) with macular oedema.

The PBS subsidises aflibercept, brolucizumab, faricimab and ranibizumab for patients with subfoveal choroidal neovascularisation.

The PBS subsidises imatinib, ripretinib and sunitinib for patients with gastrointestinal stromal tumour.

The PBS subsidises tocilizumab for patients with active giant cell arteritis.

The PBS subsidises somatropin for patients with childhood onset or late onset of severe growth hormone deficiency.

The PBS subsidises somatrogon and somatropin for eligible paediatric patients with severe growth hormone deficiency.

The PBS subsidises lanadelumab for patients with hereditary angioedema type 1 or 2.

The PBS subsidises adalimumab for patients with moderate to severe hidradenitis suppurativa.

The PBS subsidises nintedanib and pirfenidone for patients with idiopathic pulmonary fibrosis (IPF).

The PBS subsidises avatrombopag, eltrombopag and romiplostim for patients with severe chronic immune idiopathic thrombocytopenic purpura (ITP).

The PBS subsidises blinatumomab, dasatinib, imatinib, inotuzumab ozogamicin and ponatinib for patients with acute lymphoblastic leukaemia.

The PBS subsidises azacitidine, decitabine+cedazuridine and midostaurin for patients with acute myeloid leukaemia (AML).

The Pharmaceutical Benefits Scheme (PBS) subsidises idelalisib for patients with chronic lymphocytic leukaemia (CLL).

The PBS subsidises asciminib and ponatinib for patients with chronic myeloid leukaemia (CML).

The PBS subsidises azacitidine and decitabine+cedazuridine for patients with chronic myelomonocytic leukaemia (CMML).

The PBS subsidises brentuximab vedotin or vorinostat for patients with cutaneous T-cell lymphoma (CTCL), and brentuximab vedotin for patients with peripheral T-cell lymphoma (PTCL).

The PBS subsidises brentuximab vedotin for patients with relapsed or refractory Hodgkin lymphoma.

The Pharmaceutical Benefits Scheme (PBS) subsidises idelalisib for patients with refractory follicular B-cell non-Hodgkin’s lymphoma.

The Pharmaceutical Benefits Scheme (PBS) subsidises idelalisib for patients with small lymphocytic lymphoma (SLL).

The PBS subsidises brentuximab vedotin for patients with CD30 positive systemic anaplastic large cell lymphoma (sALCL).

The PBS subsidises lenalidomide, pomalidomide, elotuzumab and selinexor for patients with multiple myeloma.

The PBS subsidises lenalidomide for patients with myelodysplastic syndrome.

The PBS subsidises ruxolitinib for patients with myelofibrosis (MF).

The PBS subsidises armodafinil and modafinil for patients with narcolepsy.

The PBS subsidises biological agents for patients with non-radiographic axial spondyloarthritis.

The PBS subsidises crizotinib and entrectinib for patients with Stage IIIB (locally advanced) or Stage IV (metastatic) non-small cell lung cancer (NSCLC).

The Pharmaceutical Benefits Scheme (PBS) subsidises medicines for patients who require short or long-term opioid treatment.

The PBS subsidises eculizumab, pegcetacoplan and ravulizumab for patients with paroxysmal nocturnal haemoglobinuria (PNH).

The PBS subsidises nintedanib for patients with progressive fibrosing interstitial lung disease (PF-ILD).

The PBS subsidises biological agents for patients with severe chronic plaque psoriasis.

The PBS subsidises riociguat for patients with chronic thromboembolic pulmonary hypertension (CTEPH).

The PBS subsidises a range of medicines for patients with pulmonary arterial hypertension (PAH).

The PBS subsidises imatinib for patients with rare diseases.

The PBS subsidises mecasermin for paediatric patients with severe growth failure with primary insulin-like growth factor-1 deficiency (IGFD).

The PBS subsidises teduglutide for patients with type III short bowel syndrome with intestinal failure.

The PBS subsidises larotrectinib for patients with solid tumours that are confirmed to be neurotrophic tropomyosin receptor kinase (NTRK) gene fusion positive.

The PBS subsidises nusinersen, onasemnogene abeparvovec, and risdiplam for patients with spinal muscular atrophy (SMA).

The PBS subsidises daratumumab for patients with newly diagnosed systemic light chain amyloidosis.

The PBS subsidises biological agents for patients with moderate to severe ulcerative colitis.

The PBS subsidises omalizumab for patients with severe chronic spontaneous urticaria.

The PBS subsidises burosumab for patients with X-linked hypophosphataemia (XLH).